Opthea (ASX:OPT) 3-Year ROIIC % : 8,584.39% (As of Jun. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Opthea 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Opthea's 3-Year ROIIC % for the quarter that ended in Jun. 2023 was 8,584.39%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Opthea's 3-Year ROIIC % or its related term are showing as below:

ASX:OPT's 3-Year ROIIC % is ranked better than
99.44% of 1418 companies
in the Biotechnology industry
Industry Median: -15.195 vs ASX:OPT: 8584.39

Opthea 3-Year ROIIC % Historical Data

The historical data trend for Opthea's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea 3-Year ROIIC % Chart

Opthea Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

3-Year ROIIC %

Get a 7-Day Free Trial

-167.38

-1,046.18

-174.71

2,296.36

8,584.39

Opthea Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
3-Year ROIIC %	Get a 7-Day Free Trial															-	2,296.36	-	8,584.39	-

Competitive Comparison of Opthea's 3-Year ROIIC %

For the Biotechnology subindustry, Opthea's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Opthea's 3-Year ROIIC % falls into.

Opthea 3-Year ROIIC % Calculation

Opthea's 3-Year ROIIC % for the quarter that ended in Jun. 2023 is calculated as:

3-Year ROIIC %	=	3-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	3-Year Incremental Invested Capital^**
	=	( -214.6197939 (Jun. 2023) - -16.3204384 (Jun. 2020) )	/	( 1.648 (Jun. 2023) - 3.958 (Jun. 2020) )
	=	-198.2993555	/	-2.31
	=	8,584.39%^***

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Opthea (ASX:OPT) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Opthea 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Opthea's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea (ASX:OPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » 3-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.